- KR₩711bn
- KR₩967bn
- KR₩1tn
S.Korea finds no link between flu shot, boy's death as toll rises (updated)
Brief: Pharma Mar: Boryung Pharmaceutical Announces Superior Potent Results For Plitidepsin Against Sars-Cov-2
Brief: Boryung Pharm Agrees To Terminate $70 Mln Worth Contract With Novartis' Unit In Southeast Asia
Brief: Boryung Pharm Says Terminates $70.5 Mln Supply Contract With Jordan's Rampharma
CEO
Brief: Boryung Pharm to buy back shares at 5.57 bln won
Brief: Pharma Mar and South Korea's Boryung Pharm sign licensing deal for Zepsyre
Brief: Boryung Pharm signs contract worth 70.25 bln won
Brief: Ergomed and Boryung Pharmaceutical Co enter agreement to commercialise Ergomed's haemostat products in South Korea
Brief: Boryung Pharm to pay annual dividend as 200 won/share for FY 2016
Brief: Boryung Pharm says change of top shareholder to Boryung Holdings
Brief: Boryung Pharm signs 82.97 bln won contract with Rampharma
Brief: Boryung Pharm receives patent
Brief: Boryung Pharm says issuance of bonus shares
Brief: Boryung Pharm receives patent
Brief: Boryung Pharm sees 2016 full year revenue to be 420 bln won
Brief: Pharma Mar and Boryung Pharm sign licensing deal for Aplidin in South Korea
Brief: Boryung Pharm signs contract with STENDHAL
Brief: Boryung Pharm receives patent